Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study.

AIM To investigate the treatment pattern and safety of tafluprost for glaucoma and ocular hypertension (OH) in clinical practice in China. METHODS This post-marketing observational study included patients who received tafluprost to lower intraocular pressure (IOP) within 30d between September 2017 and March 2020 in 20 hospitals in China. Adverse drug reactions (ADRs) during tafluprost treatment and within 30d after the treatment were collected. RESULTS A total of 2544 patients were included in this study, of them 58.5% (1488/2544) had primary open angle glaucoma (POAG), 21.9% (556/2544) had OH and 19.7% (500/2544) used tafluprost for other reasons. Of 359 ADRs occurred in 10.1% (258/2544) patients, and no serious adverse event occurred. The most common ADR was conjunctival hyperemia (128 ADRs in 124 patients, 4.9%). Totally 1670 participants (65.6%) combined tafluprost with carbonic anhydrase inhibitors (CAIs; 37.1%, 620/1670), sympathomimetics (33.5%, 559/1670), β-blockers (33.2%, 555/1670), other prostaglandin analogs (PGAs; 15.6%, 260/1670) and other eye drops (15.1%, 253/1670). The highest incidence of conjunctival hyperemia was noted in patients who received tafluprost in combination with other PGAs (23 ADRs in 23 patients, 8.8%, 23/260) and the lowest was in combination with CAIs (16 ADRs in 16 patients, 2.6%, 16/620). Tafluprost was applied in primary angle-closure glaucoma (41.6%, 208/500), after glaucoma surgery (17.8%, 89/500) and after non-glaucoma surgery (15.8%, 79/500). CONCLUSION Tafluprost is safe for POAG and OH, and tolerable when combined with other eye drops and under various clinical circumstances.

[1]  Xinghuai Sun,et al.  Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China , 2022, BMC Ophthalmology.

[2]  C. Costagliola,et al.  Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma , 2022, Journal of clinical medicine.

[3]  European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition , 2021, The British journal of ophthalmology.

[4]  M. Spitzer,et al.  OCT angiography analysis of retinal vessel density in primary open-angle glaucoma with and without Tafluprost therapy , 2020, BMC Ophthalmology.

[5]  N. Ruangvaravate,et al.  Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients , 2020, Clinical ophthalmology.

[6]  H. Lemij,et al.  Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study , 2020, Advances in Therapy.

[7]  J. A. Tumbocon,et al.  Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines , 2019, Clinical ophthalmology.

[8]  Jianjun Tang,et al.  Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model. , 2019, The Lancet. Global health.

[9]  D. D. Khoziev,et al.  [Efficacy and safety of travoprost in patients with primary open-angle glaucoma]. , 2019, Vestnik oftalmologii.

[10]  R. Sihota,et al.  Simplifying “target” intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma , 2018, Indian journal of ophthalmology.

[11]  I. Rudan,et al.  National and subnational prevalence and burden of glaucoma in China: A systematic analysis , 2017, Journal of global health.

[12]  Y. Kuwayama,et al.  Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence , 2017, Advances in Therapy.

[13]  L. Gan,et al.  Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy. , 2016, International journal of ophthalmology.

[14]  Sheridan M. Hoy.  Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension , 2015, Drugs.

[15]  Xinghuai Sun,et al.  [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)]. , 2015, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology.

[16]  G. Holló,et al.  Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma , 2015, Current medical research and opinion.

[17]  N. Pfeiffer,et al.  A 6-Month Study Comparing Efficacy , Safety , and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0 . 0015 % and Timolol 0 . 5 % versus Each of Its Individual Preservative-Free Components , 2014 .

[18]  Y. Kuwayama,et al.  Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety , 2014, Advances in Therapy.